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1  |  INTRODUC TION
Fluoroquinolones (FQs) are a class of broad- spectrum antimicrobials 
that have been in wide clinical use since the 1980 and are used to 
treat bacterial infections including genitourinary, respiratory, gas-
trointestinal, skin, and soft tissue infections.1,2 Although FQs are 
generally well tolerated, they have been associated with serious 
adverse events (AEs), such as tendon injuries, aortic wall injuries, 
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The aim of this study was to assess costs and health service use associated with tendon 
injuries after the use of fluoroquinolone antimicrobials in Finland during 2002– 2012. 
This retrospective observational study included data from the Finnish Pharmaceutical 
Insurance Pool's pharmaceutical injury claims. In total, 145 compensated claimants 
aged	≥18	 years	 presenting	 tendon	 injuries	 after	 the	 use	 of	 fluoroquinolones	 (FQs)	
were included in the study. Outcomes of interest were the number of outpatient visits 
to primary, secondary, tertiary, and private healthcare services, hospital days, rehabili-
tation and their costs. Regression models were used to analyze the impact of patient 
characteristics on hospital days, as well as the relationship between patient character-
istics and tendon ruptures. Direct costs of a tendon injury averaged 14,800€ and indi-
rect costs were estimated to be 9,077€ for employed claimants. Fifty- one percent of 
the claimants were hospitalized, with an average duration of 21 days. Hospitalization 
was the costliest form of health service use with an average of 9,915€ per hospital ep-
isode. Hospital days and direct costs increased with the severity of the injury. Tendon 
ruptures, in particular bilateral ruptures, required substantially more hospital days 
and their direct costs were significantly higher than those of uncomplicated tendini-
tis. Concurrent use of oral corticosteroids and increasing age were associated with a 
higher likelihood of tendon ruptures. Although rare, FQ- related tendon injuries can 
result in considerable costs and health service use. Medical staff should remain vigi-
lant when prescribing FQs, especially in groups at increased risk for tendon injuries.
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and neuropathies. Consequently, the European Medicines Agency 
(EMA) and the U.S. Food and Drugs Administration (FDA) have rec-
ommended several restrictions on their use.3,4,5 Tendon ruptures 
and tendinitis are rare but debilitating and possibly costly AEs that 
have been strongly associated with the use of FQs. According to a 
recently published cohort and nested case– control study, the excess 
risk of a tendon rupture due to fluoroquinolones is about 3.7 cases 
per 10,000 person- years.6 Signs of tendinitis include tendon swell-
ing, irritation, and moderate- to- severe pain. Tendon ruptures, on the 
other hand, usually cause severe pain, weakness, and deformity of 
the affected tendon. Tendon injuries are treated with immobilization 
and/or corrective surgery.7 Both tendinitis and tendon ruptures can 
either heal completely or cause permanent damage to the tendon. 
The treatment of these serious AEs often requires both sick leave 
and health service use, which, in turn, cause potentially significant 
costs for patients and society. Previous research has shown that as-
sessments of FQ- related AE costs are scarce even though hospital-
ization is frequently required to treat AEs.8
The specific molecular pathway causing FQ- related tendon in-
juries remains unidentified. The biological antimicrobial mechanism 
of FQs is based on targeting bacterial DNA gyrase (DNA topoisom-
erase),9 and accordingly, a possible mechanism of AE is that FQs not 
only target bacterial DNA but also human DNA. A recent study has 
proposed that most FQ- related AEs could be explained by mitochon-
drial DNA effects due to the loss or inhibition of type II topoisomer-
ase Top2β.10 In addition, there is evidence of a connection between 
FQs and other collagen- associated AEs, such as aortic aneurysms, 
aortic dissections, and retinal detachments, in addition to tendon 
injuries.11 Previous research has shown that concurrent use of cor-
ticosteroids, an age of over 60 years, and chronic kidney disease are 
the risk factors for developing FQ- related tendon injuries.6,12
The aim of this study was to assess costs and health service use 
associated with tendon injuries relating to FQ antimicrobial use in 
Finland during 2002– 2012. Although FQ- related tendon injuries 
were first reported in 1983,13 as far as we know, the costs associated 
with them have previously not been studied.
2  |  MATERIAL S AND METHODS
This retrospective observational study analyzed data obtained from 
the Finnish Pharmaceutical Insurance Pool's pharmaceutical injury 
claims. In Finland, patients, who suffer a pharmaceutical injury are 
entitled to compensation, if a causality can be detected between 
the pharmaceutical and the injury. A pharmaceutical injury is a legal 
term defined as any bodily illness or injury or a psychiatric disease 
likely to result from a pharmaceutical taken by the injured party.14 
Pharmaceutical injury compensations are determined by applying 
the provisions contained in Finland's Tort Liability Act and the guide-
lines issued by the Traffic Accident Board.
The costs of FQ- related tendon injuries were evaluated from the 
Insurance Pool's compensated insurance claims from 2002 to 2012. 
FQ- related tendon injury costs were borne by the Social Insurance 
Institution of Finland, municipalities, employers, patients, and the 
Finnish Pharmaceutical Insurance Pool. Of these payers, the latter 
is a secondary insurance system and only compensates patient costs 
relating to pharmaceutical injuries, which are not covered by other 
institutions. These costs include excess healthcare and travel costs, 
temporary incapacity compensation (pain and suffering), permanent 
functional and cosmetic incapacity, loss of income, and loss of life 
compensation. In order to receive compensation, the pharmaceutical 
injury claim must adhere to the terms and conditions of the Finnish 
Pharmaceutical Insurance Pool. For example, the pharmaceutical in-
jury claim must be submitted within 3 years of the claimant becoming 
aware of the injury or no later than 10 years after discontinuing tak-
ing the pharmaceutical. Additionally, no compensation is rewarded 
if the pharmaceutical injury is regarded as tolerable in relation to 
the nature and severity of the illness being treated.14 Health service 
use in Finland consists of visits to public, private, and occupational 
healthcare. Finland's publicly funded healthcare system is divided 
into three levels and consists of primary health centers, secondary 
central hospitals, and tertiary university hospitals. The healthcare 
system is organized by municipalities and divided into 21 larger hos-
pital districts and five university hospitals. The private healthcare 
sector is much smaller and less frequently used. Additionally, em-
ployers are obliged to organize and fund occupational healthcare for 
employees. In this study, FQ- related AE costs were examined from a 
societal perspective as all AE- related costs, regardless of whom they 
fall on. FQ- related AE costs were divided into direct and indirect 
societal costs.
Direct societal costs of a FQ- related tendon injury episode were 
the primary outcome variable of the study, while other outcomes 
included the amount of outpatient visits to primary and private 
healthcare, visits to secondary and tertiary care, hospital days, re-
habilitation and their costs in addition to travel costs. Besides di-
rect tangible costs, intangible costs consisting of temporary and 
permanent incapacity compensation and time costs were quantified 
and added to direct costs. Outpatient visits and hospitalizations 
were valued with the unit costs of social and healthcare services in 
Finland.15,16,17 Travel costs were quantified by calculating the dis-
tance to the used health service providers and multiplied by the 
Finnish Tax Administrations annually defined kilometer allowance.18 
Time costs comprised the time spent travelling to the healthcare fa-
cility, the time receiving treatment and waiting time. The estimate 
represents the age- specific value of lost time or opportunity costs. 
The approximations of time costs are based on Finnish estimates,19 
which were adjusted to 2017 euro with the index of wage and salary 
earnings.
Indirect costs of the employed claimants were estimated ac-
cording to the friction cost approach.20 Indirect costs accounted for 
the loss of productivity due to FQ- related tendon injuries during a 
friction period when a substituting employee was searched to re-
place the injured employee. The average friction period in hours was 
multiplied by the average hourly loss productivity estimate based 
on the Statistics Finland's average earnings and average social costs 
paid by the employer.21 Average Finnish earnings were chosen due 
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to lack of salary information in the data. The friction period was es-
timated from Statistics Finland's Employment service statistics22 
and following Tan et al.,23 an additional 4- week period was added 
to estimate the time employers require to decide to open a vacancy. 
Due to elasticity between labor time and labor productivity, we ap-
plied a 0.8 elasticity measurement to indirect costs, as suggested by 
Koopmanschap et al.20
Previous studies have shown hospitalization to be a costly 
form of health service use.24,25 As there was a high occurrence of 
no hospital days in the dataset, a two- part model was built with R 
(version 3.6.2.) to predict hospitalization and the length of hospital 
stay. Additionally, two Generalized linear models (glm) were built to 
estimate the association of tendon ruptures and specifically bilat-
eral ruptures with patient characteristics. Several subgroup analyses 
were done to various subsets of claimants, so that their age, sex, 
use of oral corticosteroids, the number of co- morbidities or the flu-
oroquinolone derivative used could be taken into account. All costs 
were converted to 2017 euro.
3  |  RESULTS
3.1  |  Claimants
In	 total,	 145	 compensated	 claimants	 aged	 ≥18	 years	 presenting	
tendon injuries classified as tendinitis (n = 52) or tendon ruptures 
(n = 93) after the use of fluoroquinolones were included in the study, 
after excluding 25 + 14 Figure 1. Sixteen percent of the included 
claimants (n = 23) suffered bilateral ruptures. Ninety- nine of the 
claimants were men and 46 were women and their average age was 
66.8 years (range 21– 87). Tendon injuries were reported in connec-
tion with all FQs currently on the market in Finland. In all, 121 cases 
(83%) were associated with levofloxacin, 13 (9%) with ciprofloxacin, 
7 (5%) with norfloxacin, 2 (1%) with ofloxacin, and 2 (1%) with moxi-
floxacin. The majority of the claimants (52%) were treated for res-
piratory infections Figure 2. Co- morbidities were common, and only 
10% of the claimants did not have a pre- existing health condition, 
while 45% had been diagnosed with a chronic lung disease. A total of 
eight claimants died during the compensation claim process. Claims 
were filed from all Finnish hospital districts. In this study, 97% of 
the injuries were associated with Achilles tendons. Other affected 
tendons included those of the quadriceps and tibialis posterior mus-
cles and the rotator cuff. Tendon injuries occurred on average within 
3 weeks of the first dose of FQs (median 10 days) but ranged be-
tween 24 h and 20 years.
3.2  |  Direct costs and health service use
The estimated average direct societal cost of a FQ- related tendon 
injury episode per claimant, including incapacity compensation, 
was 14,800€. Without incapacity compensation, a FQ- related ten-
don injury amounted to 8744€. The total direct costs associated 
with FQ- related tendon injuries among claimants were 2,146,057€. 
Hospitalization was the costliest form of health service use. The 
claimants frequently visited a primary care facility (331 visits) and 
rehabilitation, such as physical and lymphatic drainage therapy (686 
visits). The averages of health service use and costs are presented in 
Table 1. Of all the claimants, 74 (51%) were evaluated to have per-
manent tendon injuries due to FQ use, and 74 (51%) claimants were 
hospitalized, with an average duration of hospitalization of 21 days 
(range 1– 87). Tendon ruptures (n = 93) were most often treated 
F I G U R E  1 Study	eligibility	and	flow	diagram	of	the	selection	
process of claimants
F I G U R E  2 Indications	for	FQ	use	in	the	study
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conservatively (equinus cast for 3– 9 weeks), while 33 (23%) claim-
ants’ tendon injuries were treated with surgery.
3.3  |  Indirect costs
Fourteen percent (20) of the claimants were employed at the time of 
their FQ- related AEs and the Insurance Pool compensated losses of 
income due to FQ- related tendon injuries in the case of six claimants 
(aged 39– 66 years), which amounted to an average cost of almost 
50,000€. In one case, the tendon injury led to permanent disability 
pension payments. Sick leave data were available for 16 claimants, 
whose sick leave lasted for an average of 78 days (range 1– 331 days).
The average productive work time of an employee in Finland is 
estimated to be 7.25 h per day, 5 days a week. The estimated fric-
tion period was thus 8 + 4 weeks, which amounted to 12 × 5 × 7.25 
productive hours, that is 435 h. The average loss of productivity cost 
estimate was 26.08€/hour. Consequently, the indirect costs of a 
friction period would have amounted to 11,346€. When these costs 
were multiplied by the elasticity measurement 0.8, indirect costs 
of a FQ- related tendon injury for an employed person amounted to 
9077€ per episode.
3.4  |  Statistical analyses
Dichotomous and continuous independent variables were selected 
to determine the impact of known risk factors, AE severity and AE 
year on hospitalization. As approximately half of the claimants had 
no hospital days and the data exhibited over dispersion, a two- part 
model was built to combine the presence of excess zeros and the 
negative binomial distribution of counts in the data (Table 2). The 
first part, the binomial logit model, predicted the probability of no 
hospitalization for all claimants (n = 145). The second part, a zero- 
truncated negative binomial model, predicted the length of hospital 
stay for those claimants (n = 74) who had at least one day of hos-
pitalization. Negative and positive coefficient estimate variation is 
explained by the logit model modeling the probability of zero and 
the zero- truncated modeling a positive count. The results of the 
two- part model indicated that claimants who had a tendon rupture 
had significantly smaller odds to avoid hospitalization that those 
with tendinitis (logit model OR = 0.3044, p = .00316) as well as a 
4.063 time increase in length of hospital stay (zero- truncated model 
IRR = 4.063, p = .000053), given that the other variables are held 
constant in the model. Additionally, advancing age and having co- 
morbidities made claimants more likely to have longer hospital days 
TA B L E  2 Analysis	of	patient	characteristics	associated	with	no	hospitalization	(logit	model)	and	length	of	hospital	stay	(zero-	truncated	
model) in the 145 claimants who received compensation from the Finnish Pharmaceutical Insurance Pool, 2001– 2012
Variable
Logit binomial Zero- truncated negative binomial
Estimate ± standard 
error p- value OR (95% CI)
Estimate ± standard 
error p- value IRR (95% CI)
AE year 0.140 ± 0.072 0.05139 1.1497 (1.001– 1.3283) −0.144	±	0.056 NA 0.870 (0.78– 0.97)
Male gender (1) −0.047	±	0.447 0.91636 0.954 (0.3958– 2.3069) 0.119 ± 0.331 0.718 1.13 (0.59– 2.16)
Age 0.015 ± 0.017 0.38930 1.015 (0.9809– 1.0505) 0.048 ± 0.014 0.00048 1.05 (1.02– 1.08)
Use of oral steroids 
(1)
−0.381	±	0.386 0.32268 0.689 (0.3193– 1.457) 0.141 ± 0.282 0.617 1.15 (0.66– 2.00)
Use of levofloxacin 
(1)
−0.713	±	0.958 0.45662 0.4903 (0.059– 2.94) −0.782	±	0.944 0.407 0.458 
(0.072– 2.91)
Use of ciprofloxacin 
(1)
−0.731	±	1.112 0.51077 0.4813 (0.0454– 4.002) −0.355	±	1.009 0.725 0.7013 
(0.097– 5.07)
Use of moxifloxacin 
(1)
−0.876	±	1.807 0.62761 0.4163 
(0.0087– 17.975)
−11.268	±	32.561 0.729 0.000013 (2.45e- 
33- 6.65e+22)
Use of norfloxacin Reference Reference Reference Reference Reference Reference
Use of ofloxacin (1) −0.001	±	1.737 0.99953 0.999 
(0.0241– 39.451)




−0.379	±	0.173 0.02900 0.6847 
(0.4804– 0.9517)
0.14277 ± 0.114 0.211 1.15 (0.922– 1.442)
Ruptured tendon 
(1)
−1.189	±	0.403 0.00316 0.3044 
(0.1353– 0.6618)
1.40201 ± 0.346 0.000053 4.063 (2.059– 8.017)
Intercept (a) −278.695	±	143.6 0.05236 9e- 122 
(2e- 247- 0.1764)
288.358 ± 112.82 0.011 1.707587e+125 
(1.572627e+29- 
1.854130e+221)
Intercept (b) −0.11977	±	0.245 0.625 0.871 (0.549– 1.434)
Note: Negative coefficient estimates indicate inverse relationship between predictors and outcomes.
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; OR, odds ratio.
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or less likely to avoid hospitalization, respectively. The prescribed 
FQ, use of oral steroids, or the claimant's gender had no significant 
influence on hospitalization in this model. Norfloxacin was used as 
a reference variable in categorizing FQs. Changing the reference FQ 
did not alter the results.
Subgroup analyses were consistent with the results of the 
above models. Claimants with tendon ruptures required a mean of 
15 days in hospital, and their total direct costs amounted to an av-
erage of 19,183€, whereas claimants with tendinitis were hospital-
ized less frequently, for an average of 2 days and with an average 
direct cost of 6963€. Bilateral tendon ruptures (n = 23) were the 
costliest subgroup. These claimants required hospitalization for an 
average of 25 days and their total direct costs averaged 25,731€. 
There were no substantial differences between males and females, 
different ages, treatment options, or AE years. However, claimants 
with co- morbidities had on average 11 hospital days in comparison 
to healthy claimants who had only 2 hospital days. Figure 3 provides 
an illustration of the impact of tendinitis, in addition to single and 
bilateral tendon rupture on the amount of hospital days and total 
direct costs.
Glm logit models predicting tendon ruptures among the claim-
ants showed that advancing age slightly and taking oral corticoste-
roids more prominently increased the odds of suffering a tendon 
rupture (OR = 1.035 and OR = 2.55, respectively) (Table 3). The 
impact of concurrent oral steroid use was more substantial among 
claimants with bilateral tendon ruptures (OR = 3.98, p = .00808) 
(Table 4). The number of co- morbidities, and again, the prescribed 
FQs, AE year, and claimant gender were not statistically significant 
in these models.
4  |  DISCUSSION
Our study found that the 145 claimants with tendon injuries had an 
average of 14,800€ direct costs in addition to the indirect costs that 
were estimated to be 9077€ for employed claimants. Fifty- one per-
cent were hospitalized, with an average duration of 21 hospital days. 
Hospitalization was the costliest form of health service use amount-
ing to an average of 9915€ per hospital episode. Advancing age and 
having co- morbidities made claimants more likely to have longer 
hospitalizations or less likely to avoid hospitalization altogether. The 
prescribed FQ, use of oral corticosteroids, or the claimant's gender 
had no significant influence on hospitalization.
The number of FQ prescriptions has almost halved during the 
2010s with all antibiotic prescribing steadily declining in Finland, 
and during the past few years, FQs have comprised approximately 
5% of antibiotic prescriptions.26 Tendon injuries were first con-
nected to norfloxacin in 1983 and have since been associated with 
all FQs currently on the market.13,27 Unlike many other drug- related 
AEs, FQ- related tendon injuries are generally easy to detect, and 
the causal effect between drug and AE is often explicit. Therefore, 
the pharmaceutical insurance claims were mostly compensated and 
only rejected if the claimant did not provide timely documentation 
or if the resulted tendon injury was regarded as tolerable in rela-
tion to the severity of the treated infection. The underreporting of 
AEs poses a significant problem for research relating to AEs and 
pharmaceutical injuries. A larger sample size would fortify the evi-
dence and provide more robust estimates. Since 2012, the handling 
of pharmaceutical injury insurance claims was taken over by the 
Finnish Co- operative for Pharmaceutical Injury Indemnities from 
the Insurance Pool, which was in force since 1984. Approximately 
200 pharmaceutical injury insurance claims are filed annually, which 
may suggest that many injuries remain both unidentified and un-
compensated, and that the compensation system continues to be 
relatively unknown. According to a systematic review published 
in 2006, 94% of all AEs possibly elude reporting.28 Consequently, 
the 160 FQ- related tendon injury claims filed to Insurance Pool be-
tween 2002 and 2012 were most likely only a small fraction of the 
actual amount29 and to make assumptions about the entire costs 
associated with FQ- related tendon injury costs based on this data 
would be misguided. Similar no- fault pharmaceutical injury insur-
ances are in use for example in Sweden, Norway, and Denmark. 
Unit costs relating to healthcare systems are country- specific and 
for this reason, costs presented in the results are directly applicable 
only to Finland. However, health service use, such as the number of 
clinic visits and hospital days are can be transferred, particularly if 
the study population is comparable.
As studies have shown drug- related AEs to be a major clinical 
and economic problem,30,31 there is a need for published literature 
F I G U R E  3 Impact	of	tendinitis	and	tendon	rupture	on	hospital	
days and total direct costs in the 145 claimants who received 
compensation based on the Finnish Pharmaceutical Insurance 
Pool's pharmaceutical injury claims 2002– 2012
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regarding societal costs associated with drug- related AEs. Lost pro-
ductivity was only compensated to six claimants, and there was sub-
stantial variation and missing documentation of earnings. Therefore, 
average earnings from Finland were chosen to provide a more 
realistic average estimate of indirect costs. However, the direct 
costs in the study were true societal costs based on real- world evi-
dence. Economic evaluations of interventions have a significant role 
when implementing products and practices to healthcare systems. 
Methods such as cost- benefit, cost- effectiveness, and cost- utility 
analyses have become standards for prioritizing and comparing in-
terventions, with the latter two capturing the element of patient 
reported quality of life. However, cost- of illness studies, such as 
this, benefit decision- making from an entirely different perspective, 
namely, the economic burden to the society. Incapacity compensa-
tions offer a glimpse of the value of health- related quality of life lost 
due to an AE, nonetheless, they cannot be used as a proxy.
At present, clinicians are more likely to avoid prescribing FQs 
to risk groups than in 2012, due to EMA and FDA recommenda-
tions, as well as improved general awareness of the AEs. In addition, 
treatment practices of tendon injuries have changed slightly toward 
favoring conservative treatment.32 Yet, a recent study by Westin 
et al.33 has found patients treated with surgery to have a consis-
tently better health- related quality of life compared with those 
treated conservatively during a one- year follow- up. However, it ap-
pears that treatment choice does not have a major impact on the 
costs because both immobilization and surgery required an equally 
TA B L E  3 Analysis	of	patient	characteristics’	association	with	tendon	ruptures	in	the	145	claimants	who	received	compensation	based	on	
the Finnish Pharmaceutical Insurance Pool's pharmaceutical injury claims 2002– 2012
Variable Estimate ± standard error p- value OR (95% CI)
AE year −0.0732	±	0.0716 0.3067 0.929 (0.806– 1.07)
Male gender 0.52851 ± 0.4399 0.2296 1.67 (0.715– 4.05)
Age 0.03504 ± 0.0172 0.0421 1.035 (1.002– 1.072)
Use of oral steroids 0.93709 ± 0.4125 0.0231 2.55 (1.16– 5.89)
Use of levofloxacin −0.4227	±	0.9344 0.6510 0.655 (0.095– 4.08)
Use of ciprofloxacin −0.91659	±	1.0877 0.3994 0.399 (0.044– 3.34)
Use of moxifloxacin −0.5060	±	2.1187 0.8112 0.603 (0.009– 4.164)
Use of norfloxacin Reference Reference Reference
Use of ofloxacin 14.17927 ± 902.301 0.9875 1,438,735 (4.23e- 55- NA)
Number of co- morbidities 0.1419 ± 0.169 0.4003 1.15 (0.835– 1.62)
Intercept 144.508 ± 143.51 0.3139 5.74e+62 (4.79e- 60 
2.91e+186)
Note: Negative coefficient estimates indicate inverse relationship between predictors and outcomes.
Abbreviations: CI, confidence interval; OR, odds ratio.
TA B L E  4 Analysis	of	patient	characteristics’	association	with	bilateral	tendon	ruptures	from	the	145	claimants	who	received	
compensation based on the Finnish Pharmaceutical Insurance Pool's pharmaceutical injury claims 2002– 2012
Variable Estimate ± standard error p- value OR (95% CI)
AE year −0.1613	±	0.098 0.09971 0.851 (0.694– 1.023)
Male gender 0.3561 ± 0.6171 0.56396 1.4277 (0.4505– 5.2147)
Age 0.0253 ± 0.0271 0.34990 1.02567 (0.9749– 1.0855)
Use of oral steroids 1.38169 ± 0.5217 0.00808 3.98 (1.47– 11.68)
Use of levofloxacin 15.2212 ± 1423.56 0.99147 4,078,675 (6.291e- 26 
5.461e+180)
Use of ciprofloxacin 15.211 ± 1423.56 0.99147 403,8437 (4.353e- 29- NA)
Use of moxifloxacin −0.82358	±	2724.65 0.99976 0.439 (3.028e- 46 - NA)
Use of norfloxacin Reference Reference Reference
Use of ofloxacin −1.49990	±	2913.87 0.99959 0.223 (2.28e- 49- NA
Number of co- morbidities 0.09090 ± 0.211 0.66723 1.095 (0.71– 1.65)
Intercept 303.91848 ± 1437.06 0.83251 9.775e+131 
(NA– 1.9461e+167)
Note: Negative coefficient estimates indicate inverse relationship between predictors and outcomes.
Abbreviations: CI, confidence interval; OR, odds ratio.
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long hospital stay in the patients who were compensated. In con-
trast to other serious AEs associated with FQs, such as cardiac tox-
icity,34 tendon injuries are not a direct cause of mortality. However, 
research has shown that traumatic injuries are associated with sig-
nificantly higher morbidity and mortality in elderly patients than in 
their younger counterparts.35 The death of eight claimants during 
the compensation claim process affected the amount of injury com-
pensations. It is a common practice for insurance companies to hold 
back the total compensation until the level of permanent disability 
has been evaluated. In such circumstances, the cost of a tendon in-
jury episode will be underestimated.
Although the number of levofloxacin- based claims might give 
the impression that its tendency to cause tendon injuries exceeds 
that of other FQs, this is likely not the case. Forty- five percent of 
the claimants had previously been diagnosed with chronic lung dis-
eases, which made them more susceptible to respiratory infections 
that were often treated with levofloxacin. Patients with chronic 
lung disease are frequently treated with inhaled glucocorticoids, as 
well as systemic glucocorticoids, which strongly increase the risk of 
FQ- associated tendon injuries. Moreover, it is possible that some 
of these patients had received fluoroquinolones on several occa-
sions. The risk of tendon injuries appears to rise with an increas-
ing number of fluoroquinolone prescriptions and with increasing 
cumulative dose6; the accumulated risk has been estimated to be 
approximately 6% with each additional day exposed to FQs.36 Thus, 
we believe that levofloxacin was overrepresented in the present 
study sample, because it was often used in high- risk patients.
EMA has recommended restricting FQ use in infections that 
are not severe, as a first- line treatment and to avoid prescribing to 
high- risk groups, such as those using corticosteroids.3 With cur-
rent recommendations, it may be possible to avoid some of the 
tendon injuries, but it is likely that in some cases there are no good 
alternatives to FQs. Moreover, some of the tendon injuries occur 
to patients who have no known risk factors, as also seen in our 
study, and, therefore, some of the cases remain unavoidable also 
with current knowledge.
Medical staff needs to stay wary of the risks in order to prevent 
and reduce fluoroquinolone- related tendon injuries, in addition to 
health service use and costs associated with them. However, due to 
the growing amount of antimicrobial- resistant bacteria, the rapid de-
cline of effective antimicrobials, and alarmingly small number of new 
discoveries, AEs and resulting costs might have to be increasingly 
tolerated in the future, in order to combat bacteria. Additionally, de-
cision makers need to be aware of the economic burden of AEs from 
a societal perspective as its extent is often underestimated.
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